Several studies have shown that HSP90 inhibitors display certain therapeutic effects on immunogenic tumors (e.g., lymphomas, melanomas) and some solid tumors [e.g., liver cancer, breast cancer, non-small-cell lung cancer (16, 17)]. This evidence concerns the gene HSP90AA1 and lymphoma.